BIOLOGICS FACILITY ROUTINE INSPECTIONS WILL SCRUTINIZE RECALL SYSTEMS, FDA SAYS; BLOOD PRODUCTS GROUP TO PRESENT RECALL PROPOSAL AT MARCH ADVISORY PANEL
Executive Summary
Routine FDA inspections of biological products manufacturing facilities will include increased evaluation of recall systems to determine appropriateness and efficacy.